Itraconazole (PUR1900)
Small molecule
Evidence outlook
Phase 2 study terminated, no active studies registered
The furthest-phase study registered for this program (NCT03960606) was terminated, and no study is currently active on the registry. No evidence signal is assigned from a stopped study. Check the registry record for the sponsor's stated reason.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT03960606 NCT03960606 · Asthma Registry: NCT03960606 | 2 | Incidence of treatment-emergent adverse events (From Day 1 through Follow Up (which is 7 to 10 days after the last dose)); Incidence of intraday FEV1 declines (From Day 1 through Follow Up (which is 7 to 10 days after the last dose)); Respiratory rate (From Day 1 through Follow Up (which is 7 to 10 days after the last dose)); Blood pressure (From Day 1 through Follow Up (which is 7 to 10 days after the last dose)); Heart rate (From Day 1 through Follow Up (which is 7 to 10 days after the last dose)); Oxygen saturation (From Day 1 through Follow Up (which is 7 to 10 days after the last dose)); Physical examination findings (From Day 1 through Follow Up (which is 7 to 10 days after the last dose)); Clinical laboratory test results (From Day 1 through Follow Up (which is 7 to 10 days after the last dose)); 12-Lead electrocardiogram findings (From Day 1 through Follow Up (which is 7 to 10 days after the last dose)) 2020-07-14 | Results not posted; external-source review pending | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 2 (1)
What this study did
Phase 1 (1)
What this study did
Competitive landscape
This drug's own stage for Allergic Bronchopulmonary Aspergillosis: Phase 2. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Itraconazole (PUR1900): this drug | Phase 2 | Small molecule | fungal CYP51 (lanosterol 14α-demethylase) | not yet graded | No reviewed efficacy summary in this indication | |
| Voriconazole (ZP-059) | Phase 1 | Small molecule | fungal CYP51 / lanosterol 14-alpha-demethylase | Weak signal | Featured results are safety only in this race |
Upcoming events
No upcoming readouts on record for this asset.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent